obesity drug news today glp-1 october 27 2025 The Obesity-Drug Revolution Is Stalling GLP-1 Genetics: How Genes Affect
Description
The first goal of these trials was to prove GLP-1 receptor agonists cardiovascular safety, and majority of CVOTs were designed as non-inferiority trials
While injectable GLP-1s work well for weight loss, keeping the weight off after discontinuing the therapies is challenging
There was no restriction based on the original language of the article
New agents like triple agonist peptides are under investigation
GLP-1 receptor agonist (incretin mimetic) The pathways GLP-1 S acts on and what each one does
However, there were fewer kidney events in the GLP-1RA group (38.2 versus 44.2%
